ClinicalTrialsFinder
RecruitingPhase 1Phase 2NCT04033302

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies

Sponsor

Shenzhen Geno-Immune Medical Institute

Enrollment

30 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

Acute Myeloid LeukemiaNK-Cell LymphomaT-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic Lymphoma

Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cell therapy against CD7-positive hematological malignancies using CD7 specific CAR T cells. The study also aims to learn more about the function of CD7 CAR T cells and their persistence in patients of hematological malignancies.

Eligibility

Min Age: 6 MonthsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called CD7-specific CAR gene-engineered T cells for people with acute myeloid leukemia, nk-cell lymphoma, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 6 Months to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALCD7-specific CAR gene-engineered T cells

Infusion of CD7-specific CAR-T cells

Locations(1)

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04033302

Related Trials

CIML NK Cells With Venetoclax for AML

NCT061528092 locations

Motixafortide for MRD Sensitization in AML

NCT073929701 location

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

NCT0393437223 locations

A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia

NCT051896391 location

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

NCT065610741 location